ALARMONYNCT07915791
A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
Notable Recruitment opened Show 4 more changesShow less
- Trial sites expanded: 0 → 10 locations
- Start date changed from estimate of Nov 9, 2026 to Oct 29, 2026
- Primary completion date: Mar 16, 2029 to Mar 7, 2029
- Study completion date: Feb 15, 2030 to Feb 6, 2030
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Annualized Rate of Moderate/severe Exacerbations in Former Smokers
Timeframe: Up to 72 weeks
Secondary (14)
Number of Participants with Serious Adverse Events and Adverse Events in All Comers (Former and Current smokers) with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG) in All Comers (Former and Current smokers) with Moderate to Severe COPD
Time to First Exacerbation in Former Smokers with Moderate to Severe COPD
Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in Former Smokers with Moderate to Severe COPD
Change from Baseline in SGRQ-C total score at Week 24 in Former Smokers with Moderate and Severe COPD
Show 9 moreShow less
Change from baseline in the COPD Assessment Test (CAT) Score at Week 24 in Former Smokers with Moderate to Severe Smokers
Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in Former Smokers with Moderate to Severe COPD
Annualized rate of Moderate/Severe Exacerbations in all Comers (Former and Current smokers)
Time to First Exacerbation in all Comers (Former and current Smokers) with Moderate to Severe COPD
Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) at Week 24 in all comers (Former and Current Smokers) with Moderate to Severe COPD
Change from Baseline in SGRQ-C total score at Week 24 in all Comers (Former and Current Smokers) with Moderate and Severe COPD
Change from baseline in the CAT Score at Week 24 all Comers (Former and Current Smokers) with Moderate to Severe Smokers
Change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) score at Week 24 in all comers (Former and current Smokers) with Moderate to Severe COPD
Serum concentrations of GSK3862995B and GSK5784283 in all comers (former and current smokers) with moderate to severe COPD
Arms and interventions
GSK3862995B co-administered with GSK5784283Experimental
Participants will receive co-administration of GSK3862995B and GSK5784283 in addition to their standard of care (SoC) triple therapy for COPD.
PlaceboPlacebo comparator
Participants will receive a matching placebo in addition to their SoC triple therapy for COPD.
Drugs: GSK3862995B, GSK5784283, Placebo
Sites
10 sites in 2 countries
United States 8, United Kingdom 2